Table 5.
Adjusted odds ratio of hospitalized heart failure associated with use of cilostazol and NSAIDs among different subgroups.
| Men (N = 22,911) |
Women (N = 24,595) |
P-values for interaction | |||
|---|---|---|---|---|---|
| Adjusted OR | 95% C.I. | Adjusted OR | 95% C.I. | ||
| Cilostazol | 1.43 | 1.11–1.84 | 1.29 | 1.03–1.63 | 0.56 |
| NSAIDs | 1.67 | 1.57–1.77 | 1.70 | 1.61–1.80 | 0.65 |
|
Age ≥ 65 (N = 35,718) |
Age < 65 (N = 11,788) |
||||
| Cilostazol | 1.37 | 1.13–1.65 | 1.27 | 0.88–1.85 | 0.72 |
| NSAIDs | 1.68 | 1.60–1.76 | 1.69 | 1.56–1.85 | 0.69 |
|
Patients with heart failure (N = 9,164) |
Patients without heart failure (N = 38,342) |
||||
| Cilostazol | 1.65 | 1.10–2.47 | 1.29 | 1.07–1.56 | 0.28 |
| NSAIDs | 1.66 | 1.51–1.84 | 1.70 | 1.62–1.78 | 0.61 |
|
Patients with chronic kidney disease (N = 9,757) |
Patients without chronic kidney disease (N = 37,749) |
||||
| Cilostazol | 1.52 | 1.14–2.04 | 1.27 | 1.03–1.56 | 0.33 |
| NSAIDs | 1.55 | 1.41–1.70 | 1.72 | 1.65–1.81 | 0.05 |
Conditional logistic regression adjusted for important potential time-varying confounding variables including pioglitazone, metformin, sitagliptin, aspirin, angiotensin converting enzyme inhibitors, beta-blockers, calcium channel blockers, diuretics, nitrates, digitalis glycoside, inhaled beta-agonists, inhaled anticholinergics, aminophylline, oral corticosteroids, and systemic antibiotics. Bold values indicate statistical significance; OR, odds ratio; 95% C.I., confidence interval.